Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. Co. uses its precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a potentially registrational Phase 2 trial across multiple solid tumor types. We show 10 historical shares outstanding datapoints in our ACRV shares outstanding history coverage, used to compute ACRV market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ACRV market cap history over the course of time is important for investors
interested in comparing ACRV's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ACRV versus a peer is one thing; comparing
ACRV market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ACRV can fluctuate over the course of history.
With this page we aim to empower investors researching ACRV by allowing them to research the ACRV market cap history. |
Free ACRV Email Alerts:
Video: The Importance of Market Cap
